STAT News
On Extra Extra, STAT News is grouped with center outlets, a placement drawn from the consensus of independent media-bias raters (AllSides, Ad Fontes Media, and Media Bias/Fact Check) rather than our own opinion. Its reliability rating of A reflects a strong track record of factual, well-sourced reporting. That rating is a guide for weighing what you read here, not a verdict on any single article.
We are currently tracking 8 recent articles from STAT News, published over the past 24 hours. Recurring themes in its latest headlines include Stat and Canc.
The best way to use this profile is comparatively. Read STAT News's coverage of a story alongside how outlets on other parts of the spectrum handle the same event — the facts usually overlap, but the emphasis, language, and what gets left out often do not. Other center sources we track include BBC News, Al Jazeera, Associated Press, and Reuters.
Recent Articles (8)
STAT+: The ESMO presentation everyone’s been waiting for
Moderna and Merck's 'presidential' presentation, and other news from Day 2 of the European Society for Medical Oncology meeting in Madrid.
Opinion: Christina Applegate puts a face on one of the most consequential challenges in neurology
“The goal is not simply to diagnose MS faster. It is to get the diagnosis right,” writes Bruce Bebo.
Opinion: STAT readers on Elizabeth Holmes, cancer screening, and more
“Even if Theranos had a functioning testing machine, the economic model on which is was based would result in failure,” writes a STAT reader.
STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
In data released at ESMO, the Moderna-Merck personalized mRNA cancer vaccine reduced recurrence-free survival and the time until distant metastasis occurred.
STAT+: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclear
The American Diabetes Association has issued two explanations, two reviews and an apology over its June convention. A Friday report adds new twists.
STAT+: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial
Where should the safety bar be for studies investigating CAR-T therapies for autoimmune conditions?
STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds
Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.
STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.